Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria

Arienne Mirmiran,[1] Antoine Poli,[1-3*] Cecile Ged,[4,5] Caroline Schmitt,[1-3] Thibaud Lefebvre,[1-3] Hana Manceau,[1,2,6] Raêd Daher,[1-3] Boualem Moulouel,[3] Katell Peoc'h,[1,2,6] Sylvie Simonin,[1,3] Jean-Marc Blouin,[4,5] Jean-Charles Deybach,[1-3] Gaël Nicolas,[1] Hervé Puy,[1-3] Emmanuel Richard[4,5 #] and Laurent Gouya[1-3,5#]*

[1]Institut National de la Santé et de la Recherche Médicale U1149, Centre de Recherches sur l'Inflammation, Paris; [2]Université de Paris, Paris; [3]Assistance Publique-Hôpitaux de Paris, Centre Français des Porphyries, Hôpital Louis Mourier, Colombes; [4]Université Bordeaux, INSERM, BMGIC, U1035, CHU Bordeaux, Bordeaux; [5]Laboratory of Excellence Gr-Ex, Paris and [6]Assistance Publique-Hôpitaux de Paris, HUPNVS, Laboratoire de Biochimie, Hôpital Beaujon, Clichy, France

**AM and AP contributed equally as co-first authors.*

#ER and LG contributed equally as co-senior authors.

Correspondence: LAURENT GOUYA - laurent.gouya@inserm.fr

EMMANUEL RICHARD - emmanuel.richard@u-bordeaux.fr

doi:10.3324/haematol.2019.228270

Supplemental Table 1: **CD34+ differentiation medium preparation**

IMDM medium + GlutaMax Ref 31980-022 ThermoFischer Scientific

Days 0 - 6

Components	Initial concentration	Final concentration	For 10 mL of medium
AB serum	100%	3%	300 µL
Plasma	100%	2%	200 µL
Insulin	10 mg/mL	10 µg/mL	10 µL
Heparin	10 kU/mL	3 U/mL	3 µL
Transferrin	50 mg/mL	200 µg/mL	40 µL
Stem cell factor	50 µg/mL	10 ng/mL	2 µL
IL-3	20 µg/mL	1 ng/mL	0.5 µL
EPO	1000 U/mL	3 U/mL	30 µL
Penicillin/Streptomycin	100X	1X	100 µL

Days 7 - 10

Components	Initial concentration	Final concentration	For 10 mL of medium
AB serum	100%	3%	300 µL
Plasma	100%	2%	200 µL
Insulin	10 mg/mL	10 µg/mL	10 µL
Heparin	10 kU/mL	3 U/mL	3 µL
Transferrin	50 mg/mL	200 µg/mL	40 µL
Stem cell factor	50 µg/mL	10 ng/mL	2 µL
EPO	1000 U/mL	1 U/mL	10 µL
Penicillin/Streptomycin	100X	1X	100 µL

Days 11 - 14

Components	Initial concentration	Final concentration	For 10 mL of medium
AB serum	100%	3%	300 µL
Plasma	100%	2%	200 µL
Insulin	10 mg/mL	10 µg/mL	10 µL
Heparin	10 kU/mL	3 U/mL	3 µL
Transferrin	50 mg/mL	1 mg/mL	200 µL
EPO	1000 U/mL	0.1 U/mL	1 µL
Penicillin/Streptomycin	100X	1X	100 µL

Days 15 - 21

Components	Initial concentration	Final concentration	For 10 mL of medium
AB serum	100%	3%	300 µL
Plasma	100%	2%	200 µL
Insulin	10 mg/mL	10 µg/mL	10 µL
Heparin	10 kU/mL	3 U/mL	3 µL
Transferrin	50 mg/mL	1 mg/mL	200 µL
Penicillin/Streptomycin	100X	1X	100 µL

Human serum AB H4522, Sigma-Aldrich; Human plasma 70039, Stemcell Technologies; Insulin, recombinant, human 91077C, Sigma-Aldrich; Heparin sodium H3149, Sigma-Aldrich; Holo-transferrin human T4132-1G, Sigma-Aldrich; Human SCF 130-096-695, Miltelyi Biotec; IL-3, human, recombinant 2503, Stemcell Technologies; EPO PHC2054, Life Technologies

Supplemental Figure 1: **D13 erythroid cells flow cytometry analysis**. Cells were marked with anti-CD36 and anti-CD235 (Glycophorin A). Similar profiles were observed in all conditions.



Supplemental Figure 2: **D17 erythroid cell flow cytometry analysis**. Cells were marked with anti-CD36 and anti-CD235 (Glycophorin A). Similar profiles were observed in all conditions.